Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at National Institutes of Health detail research in cancer vaccines
August 20th, 2008
Researchers detail in 'Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers,' new data in cancer. According to recent research from the United States, "There is mounting evidence describing the immunosuppressive role of bulky metastatic disease, thus countering the therapeutic effects of tumor vaccine. Therefore, adjuvant immunotherapy may have a better impact on clinical outcome." "In this phase II clinical trial, we aimed to test the feasibility of using a specific mutant ras peptide vaccine as an adjuvant immunotherapy in pancreatic and colorectal cancer patients. Twelve patients with no evidence of disease...
Source: Vaccine Weekly (2008-08-20)
|
